148 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: final results from a 192-week extension study.

Autor: Wainwright, C. (AUTHOR), McColley, S. (AUTHOR), McNally, P. (AUTHOR), Powers, M. (AUTHOR), Ratjen, F. (AUTHOR), Rayment, J. (AUTHOR), Retsch-Bogart, G. (AUTHOR), Roesch, E. (AUTHOR), Ahluwalia, N. (AUTHOR), Chu, C. (AUTHOR), Scirica, C. (AUTHOR), Weinstock, T. (AUTHOR), Davies, J. (AUTHOR)
Zdroj: Journal of Cystic Fibrosis. Sep2024 Supplement 2, Vol. 23, pS82-S83. 2p.
Databáze: Academic Search Ultimate
Externí odkaz: